Here is Why Legend Biotech (LEGN) Offers Such Promising Upside

Company Overview - Legend Biotech (NASDAQ:LEGN) is a commercial-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, including hematologic malignancies and solid tumors [5]. Stock Performance and Analyst Ratings - As of December 19, Legend Biotech's stock has a consensus rating that remains bullish, with 10 out of 11 analysts assigning Buy ratings and 1 analyst assigning a Hold rating. There are no Sell ratings for the stock [2]. - The stock has an estimated 1-year average price target of $68.20, indicating a potential upside of 211% from current trading levels [2]. - Cantor Fitzgerald analyst Eric Schmidt reaffirmed an overweight stance on the stock, assigning a Buy rating with a target price of $74, suggesting a 238% upside potential at the current trading range [3]. Product and Market Insights - Management views CAR-T cell therapy, specifically Carvykti, as a unique cure for myeloma, supported by long-term survival benefit data. The increasing demand for myeloma treatment is expected to drive production scaling [4]. - The management's positive outlook on CAR-T therapy and the anticipated growth in demand are seen as factors that outweigh potential competitive threats in the market, strengthening the investment case for Legend Biotech [4].